Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Japanese Journal of Radiology
Erschienen in: Japanese Journal of Radiology 1/2020

23.09.2019 | Invited Review

Diagnostic imaging of dementia with Lewy bodies, frontotemporal lobar degeneration, and normal pressure hydrocephalus

Erschienen in: Japanese Journal of Radiology | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Neuroimaging can provide important biomarkers and is very useful for supporting dementia diagnosis. This review summarizes the neuroimaging findings of dementia with Lewy bodies (DLB), frontotemporal lobar degeneration (FTLD), and normal pressure hydrocephalus (NPH). In DLB, medial temporal atrophy is milder than that of Alzheimer’s disease. 2-fluoro-2-deoxy-d-glucose-positron emission tomography and brain perfusion single-photon emission computed tomography demonstrate hypometabolism and hypoperfusion in the occipital lobe, in addition to decreased metabolism and perfusion in the parietotemporal, posterior cingulate, precuneus, and frontal association cortices. The cingulate island sign, which shows relatively spared middle-to-posterior cingulate cortex metabolism compared with precuneus hypometabolism, is proposed to detect DLB in 2-fluoro-2-deoxy-d-glucose-positron emission tomography imaging. Reduced uptake in dopamine transporter imaging and reduced myocardial uptake in iodine-123 metaiodobenzylguanidine cardiac scintigraphy are indicative biomarkers for DLB diagnosis. Characteristic findings of FTLD include dominant frontotemporal atrophy, hypometabolism, and hypoperfusion. Most idiopathic NPH cases demonstrate disproportionally enlarged subarachnoid space hydrocephalus findings, including dilated ventricular systems, enlarged Sylvian fissures, tight sulci in the midline, and a high convexity.
Literatur
1.
2.
McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology. 2017;89(1):88–100.PubMedPubMedCentralCrossRef
3.
Hashimoto M, Kitagaki H, Imamura T, Hirono N, Shimomura T, Kazui H, et al. Medial temporal and whole-brain atrophy in dementia with Lewy bodies: a volumetric MRI study. Neurology. 1998;51(2):357–62.PubMedCrossRef
4.
Takahashi R, Ishii K, Miyamoto N, Yoshikawa T, Shimada K, Ohkawa S, et al. Measurement of gray and white matter atrophy in dementia with Lewy bodies using diffeomorphic anatomic registration through exponentiated lie algebra: a comparison with conventional voxel-based morphometry. AJNR Am J Neuroradiol. 2010;31(10):1873–8.PubMedCrossRefPubMedCentral
5.
Nakatsuka T, Imabayashi E, Matsuda H, Sakakibara R, Inaoka T, Terada H. Discrimination of dementia with Lewy bodies from Alzheimer’s disease using voxel-based morphometry of white matter by statistical parametric mapping 8 plus diffeomorphic anatomic registration through exponentiated Lie algebra. Neuroradiology. 2013;55(5):559–66.PubMedPubMedCentralCrossRef
6.
Imamura T, Ishii K, Sasaki M, Kitagaki H, Yamaji S, Hirono N, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer’s disease: a comparative study using positron emission tomography. Neurosci Lett. 1997;235(1–2):49–52.PubMedCrossRef
7.
Ishii K, Imamura T, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer’s disease. Neurology. 1998;51(1):125–30.PubMedCrossRef
8.
Ishii K, Yamaji S, Kitagaki H, Imamura T, Hirono N, Mori E. Regional cerebral blood flow difference between dementia with Lewy bodies and AD. Neurology. 1999;53(2):413–6.PubMedCrossRef
9.
Lobotesis K, Fenwick JD, Phipps A, Ryman A, Swann A, Ballard C, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology. 2001;56(5):643–9.PubMedCrossRef
10.
11.
Ishii K, Hosaka K, Mori T, Mori E. Comparison of FDG-PET and IMP-SPECT in patients with dementia with Lewy bodies. Ann Nucl Med. 2004;18(5):447–51.PubMedCrossRef
12.
O'Brien JT, Firbank MJ, Davison C, Barnett N, Bamford C, Donaldson C, et al. 18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias. J Nucl Med. 2014;55(12):1959–65.PubMedCrossRef
13.
14.
Ishii K, Ito K, Nakanishi A, Kitamura S, Terashima A. Computer-assisted system for diagnosing degenerative dementia using cerebral blood flow SPECT and 3D-SSP: a multicenter study. Jpn J Radiol. 2014;32(7):383–90.PubMedCrossRef
15.
Lim SM, Katsifis A, Villemagne VL, Best R, Jones G, Saling M, et al. The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med. 2009;50(10):1638–45.PubMedCrossRef
16.
Imabayashi E, Yokoyama K, Tsukamoto T, Sone D, Sumida K, Kimura Y, et al. The cingulate island sign within early Alzheimer’s disease-specific hypoperfusion volumes of interest is useful for differentiating Alzheimer's disease from dementia with Lewy bodies. EJNMMI Res. 2016;6(1):67.PubMedPubMedCentralCrossRef
17.
18.
Walker Z, Costa DC, Walker RW, Shaw K, Gacinovic S, Stevens T, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry. 2002;73(2):134–40.PubMedPubMedCentralCrossRef
19.
Takaya S, Sawamoto N, Okada T, Okubo G, Nishida S, Togashi K, et al. Differential diagnosis of parkinsonian syndromes using dopamine transporter and perfusion SPECT. Parkinsonism Relat Disord. 2018;47:15–211.PubMedCrossRef
20.
Shimizu S, Hirose D, Namioka N, Kanetaka H, Hirao K, Hatanaka H, et al. Correlation between clinical symptoms and striatal DAT uptake in patients with DLB. Ann Nucl Med. 2017;31(5):390–8.PubMedCrossRef
21.
van der Zande JJ, Booij J, Scheltens P, Raijmakers PG, Lemstra AW. [(123)]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies. Eur J Nucl Med Mol Imaging. 2016;43(6):1060–6.PubMedPubMedCentralCrossRef
22.
Watanabe H, Ieda T, Katayama T, Takeda A, Aiba I, Doyu M, et al. Cardiac (123)I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2001;70(6):781–3.PubMedPubMedCentralCrossRef
23.
Oda H, Ishii K, Terashima A, Shimada K, Yamane Y, Kawasaki R, et al. Myocardial scintigraphy may predict the conversion to probable dementia with Lewy bodies. Neurology. 2013;81(20):1741–5.PubMedCrossRef
24.
Shimizu S, Hirao K, Kanetaka H, Namioka N, Hatanaka H, Hirose D, et al. Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2016;43(1):184–92.PubMedCrossRef
25.
Treglia G, Cason E, Cortelli P, Gabellini A, Liguori R, Bagnato A, et al. Iodine-123 metaiodobenzylguanidine scintigraphy and iodine-123 ioflupane single photon emission computed tomography in Lewy body diseases: complementary or alternative techniques? J Neuroimaging. 2014;24(2):149–54.PubMedCrossRef
26.
Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, et al. Imaging amyloid deposition in Lewy body diseases. Neurology. 2008;71(12):903–10.PubMedPubMedCentralCrossRef
27.
Donaghy P, Thomas AJ, O'Brien JT. Amyloid PET Imaging in Lewy body disorders. Am J Geriatr Psychiatry. 2015;23(1):23–37.PubMedCrossRef
28.
Siderowf A, Pontecorvo MJ, Shill HA, Mintun MA, Arora A, Joshi AD, et al. PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders. BMC Neurol. 2014;14:79.PubMedPubMedCentralCrossRef
29.
Brooks DJ. Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography. Mov Disord. 2009;24(Suppl 2):S742–S747747.PubMedCrossRef
30.
Kantarci K, Lowe VJ, Boeve BF, Weigand SD, Senjem ML, Przybelski SA, et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging. 2012;33(9):2091–105.PubMedCrossRef
31.
Palermo G, Tommasini L, Aghakhanyan G, Frosini D, Giuntini M, Tognoni G, et al. Clinical correlates of cerebral amyloid deposition in Parkinson's disease dementia: evidence from a PET study. J Alzheimers Dis. 2019;70(2):597–609.PubMedCrossRef
32.
Ishii K, Hosokawa C, Hyodo T, Sakaguchi K, Usami K, Shimamoto K, et al. Regional glucose metabolic reduction in dementia with Lewy bodies is independent of amyloid deposition. Ann Nucl Med. 2015;29(1):78–83.PubMedCrossRef
33.
Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456–77.PubMedPubMedCentralCrossRef
34.
Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006–144.PubMedPubMedCentralCrossRef
35.
Lashley T, Rohrer JD, Mead S, Revesz T. Review: an update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations. Neuropathol Appl Neurobiol. 2015;41(7):858–81.PubMedCrossRef
36.
Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 2007;114(1):5–22.PubMedPubMedCentralCrossRef
37.
Seelaar H, Rohrer JD, Pijnenburg YA, Fox NC, van Swieten JC. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry. 2011;82(5):476–86.PubMedCrossRef
38.
McCarthy J, Collins DL, Ducharme S. Morphometric MRI as a diagnostic biomarker of frontotemporal dementia: a systematic review to determine clinical applicability. Neuroimage Clin. 2018;20:685–96.PubMedPubMedCentralCrossRef
39.
Meyer S, Mueller K, Stuke K, Bisenius S, Diehl-Schmid J, Jessen F, et al. Predicting behavioral variant frontotemporal dementia with pattern classification in multi-center structural MRI data. Neuroimage Clin. 2017;14:656–62.PubMedPubMedCentralCrossRef
40.
Moller C, Pijnenburg YA, van der Flier WM, Versteeg A, Tijms B, de Munck JC, et al. Alzheimer disease and behavioral variant frontotemporal dementia: automatic classification based on cortical atrophy for single-subject diagnosis. Radiology. 2016;279(3):838–48.PubMedCrossRef
41.
Kanda T, Ishii K, Uemura T, Miyamoto N, Yoshikawa T, Kono AK, et al. Comparison of grey matter and metabolic reductions in frontotemporal dementia using FDG-PET and voxel-based morphometric MR studies. Eur J Nucl Med Mol Imaging. 2008;35(12):2227–34.PubMedCrossRef
42.
Bruun M, Koikkalainen J, Rhodius-Meester HFM, Baroni M, Gjerum L, van Gils M, et al. Detecting frontotemporal dementia syndromes using MRI biomarkers. Neuroimage Clin. 2019;22:101711.PubMedPubMedCentralCrossRef
43.
Ishii K, Sakamoto S, Sasaki M, Kitagaki H, Yamaji S, Hashimoto M, et al. Cerebral glucose metabolism in patients with frontotemporal dementia. J Nucl Med. 1998;39(11):1875–8.PubMed
44.
Buhour MS, Doidy F, Laisney M, Pitel AL, de La Sayette V, Viader F, et al. Pathophysiology of the behavioral variant of frontotemporal lobar degeneration: a study combining MRI and FDG-PET. Brain Imaging Behav. 2017;11(1):240–52.PubMedCrossRef
45.
Verfaillie SC, Adriaanse SM, Binnewijzend MA, Benedictus MR, Ossenkoppele R, Wattjes MP, et al. Cerebral perfusion and glucose metabolism in Alzheimer's disease and frontotemporal dementia: two sides of the same coin? Eur Radiol. 2015;25(10):3050–9.PubMedPubMedCentralCrossRef
46.
Anazodo UC, Finger E, Kwan BYM, Pavlosky W, Warrington JC, Gunther M, et al. Using simultaneous PET/MRI to compare the accuracy of diagnosing frontotemporal dementia by arterial spin labelling MRI and FDG-PET. Neuroimage Clin. 2018;17:405–14.PubMedCrossRef
47.
48.
Routier A, Habert MO, Bertrand A, Kas A, Sundqvist M, Mertz J, et al. Structural, microstructural, and metabolic alterations in primary progressive aphasia variants. Front Neurol. 2018;9:766.PubMedPubMedCentralCrossRef
49.
Kobylecki C, Langheinrich T, Hinz R, Vardy ER, Brown G, Martino ME, et al. 18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease. J Nucl Med. 2015;56(3):386–91.PubMedCrossRef
50.
Ryan KA, Hammers D, DeLeon A, Bilen H, Frey K, Burke J, et al. Agreement among neuropsychological and behavioral data and PiB findings in diagnosing frontotemporal dementia. J Clin Neurosci. 2017;44:128–32.PubMedPubMedCentralCrossRef
51.
Makaretz SJ, Quimby M, Collins J, Makris N, McGinnis S, Schultz A, et al. Flortaucipir tau PET imaging in semantic variant primary progressive aphasia. J Neurol Neurosurg Psychiatry. 2018;89(10):1024–31.PubMedCrossRef
52.
Son HJ, Oh JS, Roh JH, Seo SW, Oh M, Lee SJ, et al. Differences in gray and white matter (18)F-THK5351 uptake between behavioral-variant frontotemporal dementia and other dementias. Eur J Nucl Med Mol Imaging. 2019;46(2):357–66.PubMedCrossRef
53.
Asghar M, Hinz R, Herholz K, Carter SF. Dual-phase [18F]florbetapir in frontotemporal dementia. Eur J Nucl Med Mol Imaging. 2019;46(2):304–11.PubMedCrossRef
54.
Santos-Santos MA, Rabinovici GD, Iaccarino L, Ayakta N, Tammewar G, Lobach I, et al. Rates of amyloid imaging positivity in patients with primary progressive aphasia. JAMA Neurol. 2018;75(3):342–52.PubMedPubMedCentralCrossRef
55.
Mori E, Ishikawa M, Kato T, Kazui H, Miyake H, Miyajima M, et al. Guidelines for management of idiopathic normal pressure hydrocephalus: second edition. Neurol Med Chir (Tokyo). 2012;52(11):775–809.CrossRef
56.
Ishii K, Kawaguchi T, Shimada K, Ohkawa S, Miyamoto N, Kanda T, et al. Voxel-based analysis of gray matter and CSF space in idiopathic normal pressure hydrocephalus. Dement Geriatr Cogn Disord. 2008;25(4):329–35.PubMedCrossRef
57.
Yamashita F, Sasaki M, Takahashi S, Matsuda H, Kudo K, Narumi S, et al. Detection of changes in cerebrospinal fluid space in idiopathic normal pressure hydrocephalus using voxel-based morphometry. Neuroradiology. 2010;52(5):381–6.PubMedCrossRef
58.
Ishii K, Soma T, Shimada K, Oda H, Terashima A, Kawasaki R. Automatic volumetry of the cerebrospinal fluid space in idiopathic normal pressure hydrocephalus. Dement Geriatr Cogn Dis Extra. 2013;3(1):489–96.PubMedPubMedCentralCrossRef
59.
Yamashita F, Sasaki M, Saito M, Mori E, Kawaguchi A, Kudo K, et al. Voxel-based morphometry of disproportionate cerebrospinal fluid space distribution for the differential diagnosis of idiopathic normal pressure hydrocephalus. J Neuroimaging. 2014;24(4):359–65.PubMedCrossRef
60.
Ishii K, Kanda T, Harada A, Miyamoto N, Kawaguchi T, Shimada K, et al. Clinical impact of the callosal angle in the diagnosis of idiopathic normal pressure hydrocephalus. Eur Radiol. 2008;18(11):2678–83.PubMedCrossRef
61.
Virhammar J, Laurell K, Cesarini KG, Larsson EM. The callosal angle measured on MRI as a predictor of outcome in idiopathic normal-pressure hydrocephalus. J Neurosurg. 2014;120(1):178–84.PubMedCrossRef
62.
Grahnke K, Jusue-Torres I, Szujewski C, Joyce C, Schneck M, Prabhu VC, et al. The quest for predicting sustained shunt response in normal-pressure hydrocephalus: an analysis of the callosal angle's utility. World Neurosurg. 2018;115:e717–e722722.PubMedCrossRef
63.
Yamada S, Ishikawa M, Yamamoto K. Optimal diagnostic indices for idiopathic normal pressure hydrocephalus based on the 3D quantitative volumetric analysis for the cerebral ventricle and subarachnoid space. AJNR Am J Neuroradiol. 2015;36(12):2262–9.PubMedCrossRefPubMedCentral
64.
Yamada S, Ishikawa M, Yamamoto K. Comparison of CSF distribution between idiopathic normal pressure hydrocephalus and Alzheimer disease. AJNR Am J Neuroradiol. 2016;37(7):1249–55.PubMedCrossRefPubMedCentral
65.
Iseki C, Takahashi Y, Wada M, Kawanami T, Adachi M, Kato T. Incidence of idiopathic normal pressure hydrocephalus (iNPH): a 10-year follow-up study of a rural community in Japan. J Neurol Sci. 2014;339(1–2):108–12.PubMedCrossRef
66.
Hattori T, Yuasa T, Aoki S, Sato R, Sawaura H, Mori T, et al. Altered microstructure in corticospinal tract in idiopathic normal pressure hydrocephalus: comparison with Alzheimer disease and Parkinson disease with dementia. AJNR Am J Neuroradiol. 2011;32(9):1681–7.PubMedCrossRefPubMedCentral
67.
Irie R, Tsuruta K, Hori M, Suzuki M, Kamagata K, Nakanishi A, et al. Neurite orientation dispersion and density imaging for evaluation of corticospinal tract in idiopathic normal pressure hydrocephalus. Jpn J Radiol. 2017;35(1):25–30.PubMedCrossRef
68.
Kim MJ, Seo SW, Lee KM, Kim ST, Lee JI, Nam DH, et al. Differential diagnosis of idiopathic normal pressure hydrocephalus from other dementias using diffusion tensor imaging. AJNR Am J Neuroradiol. 2011;32(8):1496–503.PubMedCrossRefPubMedCentral
69.
Ohmichi T, Kondo M, Itsukage M, Koizumi H, Matsushima S, Kuriyama N, et al. Usefulness of the convexity apparent hyper-perfusion (CAPPAH) sign in 123I-iodoamphetamine brain perfusion single photon emission computed tomography for the diagnosis of idiopathic normal pressure hydrocephalus. J Neurosurg. 2018;130:398–405.PubMedCrossRef
70.
Ishii K, Hashimoto M, Hayashida K, Hashikawa K, Chang CC, Nakagawara J, et al. A multicenter brain perfusion SPECT study evaluating idiopathic normal-pressure hydrocephalus on neurological improvement. Dement Geriatr Cogn Disord. 2011;32(1):1–10.PubMedCrossRef
71.
Rinne JO, Frantzen J, Leinonen V, Lonnrot K, Laakso A, Virtanen KA, et al. Prospective flutemetamol positron emission tomography and histopathology in normal pressure hydrocephalus. Neurodegener Dis. 2014;13(4):237–45.PubMed
72.
Kawaguchi T, Hirata Y, Bundo M, Kondo T, Owaki H, Ito S, et al. Role of computerized tomographic cisternography in idiopathic normal pressure hydrocephalus. Acta Neurochir (Wien). 2011;153(10):2041–8 (discussion 8).CrossRef
Metadaten
Titel
Diagnostic imaging of dementia with Lewy bodies, frontotemporal lobar degeneration, and normal pressure hydrocephalus
Publikationsdatum
23.09.2019
Erschienen in
Japanese Journal of Radiology / Ausgabe 1/2020
Print ISSN: 1867-1071
Elektronische ISSN: 1867-108X
DOI
https://doi.org/10.1007/s11604-019-00881-9

Weitere Artikel der Ausgabe 1/2020

Japanese Journal of Radiology 1/2020 Zur Ausgabe

Letter to the Editor

Reply to the Letter to the Editor: MRI-detected breast lesions: clinical implications and evaluation based on MRI/ultrasonography fusion technology

Original Article

Intraoperative radiotherapy (IORT) versus whole-breast external beam radiotherapy (EBRT) in early stage breast cancer: results from SEER database

Letter to the Editor

Response to Evaluation of coronary artery variations using dual-source coronary computed tomography angiography in neonates with transposition of the great arteries

Editorial

Celebrating the beginning of international journal collaboration

Invited Review

Pelvic floor dysfunctions: how to image patients?

Special Report

Guideline on the use of iodinated contrast media in patients with kidney disease 2018

Neu im Fachgebiet Radiologie

23.04.2024 | Pankreaskarzinom | Nachrichten

S3-Leitlinie zu Pankreaskrebs aktualisiert

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

13.04.2024 | Klinik aktuell | Kongressbericht | Nachrichten

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

08.04.2024 | Andrologie | Nachrichten

Wie toxische Männlichkeit der Gesundheit von Männern schadet
weitere anzeigen

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen